In Vitro Activities of Ravuconazole (BMS-207147) against 541 Clinical Isolates of Cryptococcus neoformans

The in vitro activities of the new triazole, ravuconazole (BMS-207147), were compared to those of fluconazole and itraconazole against 541 clinical isolates of Cryptococcus neoformans. Isolates were obtained from cerebrospinal fluid (396), blood (116), and miscellaneous clinical specimens (29). Over...

Fuld beskrivelse

Bibliografiske detaljer

Udgivet i:	Antimicrob Agents Chemother
Principais autores:	Yamazumi, T., Pfaller, M. A., Messer, S. A., Houston, A., Hollis, R. J., Jones, R. N.
Format:	Artigo
Sprog:	Inglês
Udgivet:	American Society for Microbiology (ASM) 2000
Fag:	Susceptibility
Online adgang:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC90171/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10991880/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.44.10.2883-2886.2000
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!